公开(公告)号：US20200061207A1

公开(公告)日：2020-02-27

申请号：US16531734

申请日：2019-08-05

Applicant: Shyam S. Mohapatra ,  Subhra Mohapatra ,  Eleni Markousta

Inventor： Shyam S. Mohapatra ,  Subhra Mohapatra ,  Eleni Markousta

IPC: A61K47/69 ,  A61K47/54 ,  A61K47/60 ,  A61P27/02 ,  A61K9/00 ,  C12N15/113 ,  A61K31/7088 ,  A61K31/4439 ,  A61K47/61 ,  A61K47/62

Abstract: A multifunctional dendrimer nanoparticle and method of treating diseases of the posterior segment of the eye is presented. The functionalized polyamidoamine (PAMAM) dendrimer effectively delivers drugs and/or genes to the posterior eye, thereby providing for the effective, non-invasive, and topical treatment of diseased in the posterior eye. The multifunctional dendrimer nanoparticle has shRNA-encoding DNA and small molecule drug encapsulated cyclodextrin complexed to the outer surface of the dendrimer for delivery to the posterior segment of the eye.

公开(公告)号：US10184942B2

公开(公告)日：2019-01-22

申请号：US13422880

申请日：2012-03-16

Applicant: Subhra Mohapatra ,  Shyam Mohapatra

Inventor： Subhra Mohapatra ,  Shyam Mohapatra

IPC: G01N33/574 ,  C07K16/28 ,  C12Q1/6886 ,  C12N15/113

Abstract: The invention pertains to biomarkers for clinical detection of malignancies, especially for early detection of cancers. More specifically, this invention pertains to the role of Natriuretic Peptide Receptor A (NPRA) in cancer (e.g., tumor) progression. Thus, the invention includes materials and methods for the detection and prognosis of malignancies. The invention also pertains to methods for treating malignancies.

公开(公告)号：US20180338996A1

公开(公告)日：2018-11-29

申请号：US15987580

申请日：2018-05-23

Applicant: SUBHRA MOHAPATRA ,  SHYAM S. MOHAPATRA ,  MAHASWETA DAS

Inventor： SUBHRA MOHAPATRA ,  SHYAM S. MOHAPATRA ,  MAHASWETA DAS

IPC: A61K35/28 ,  A61K31/4439 ,  A61P25/00

Abstract: The present invention concerns a method for treatment of traumatic brain injury (TBI) in a human or non-human animal subject, comprising administering stem or progenitor cells to the subject, such as mesenchymal stromal cells; and administering one or more PPARγ agonists, such as pioglitazone (PG), to the subject before, during, and/or after administration of the stem or progenitor cells. Another aspect of the invention concerns a pharmaceutical composition useful for treating TBI, the composition comprising stem cells or progenitor cells, such as mesenchymal stromal cells, and one or more PPARγ agonists, such as PG.

公开(公告)号：US09938526B2

公开(公告)日：2018-04-10

申请号：US15162872

申请日：2016-05-24

Applicant: Juan Sanchez-Ramos ,  Vasyl Sava ,  Shijie Song ,  Shyam S. Mohapatra ,  Subhra Mohapatra

Inventor： Juan Sanchez-Ramos ,  Vasyl Sava ,  Shijie Song ,  Shyam S. Mohapatra ,  Subhra Mohapatra

IPC: C12N15/113 ,  A61K31/713 ,  A61K9/00 ,  A61K9/107 ,  A61K9/16 ,  A61K9/50 ,  A61K49/18 ,  C12N15/88 ,  C12N15/89 ,  A61K9/51 ,  A61K31/7088 ,  A61K47/54 ,  A61K47/69 ,  A61K48/00

CPC classification number: C12N15/113 ,  A61K9/0043 ,  A61K9/1075 ,  A61K9/1611 ,  A61K9/1652 ,  A61K9/1658 ,  A61K9/50 ,  A61K9/501 ,  A61K9/5115 ,  A61K31/7088 ,  A61K31/713 ,  A61K47/541 ,  A61K47/547 ,  A61K47/6939 ,  A61K48/00 ,  A61K49/1881 ,  C12N15/88 ,  C12N15/895 ,  C12N2310/14 ,  C12N2320/32

Abstract: The compositions and methods of the disclosure particularly target the divalent metal transporter expressed on olfactory nerve terminals to transport divalent cation-coated or cation-containing nanoparticles to all regions of brain. It has been found that such divalent cation-containing nanoparticles, including those nanoparticles comprising manganese have affinity for the metal transport receptor proteins. Although this receptor has particular affinity for manganese, it is contemplated that other divalent ions, including magnesium, calcium, and the like may also be bound to such receptors leading to transport of the nanoparticles into the intracellular cytoplasm. Nanoparticles have been developed, therefore, as vehicles for parenteral delivery of genes, proteins and drugs. The present disclosure encompasses embodiments of nanoparticle-based compositions and methods for the use thereof for the delivery of genes, oligonucleotides, including but not limited to small interfering RNA, and other small molecule drugs, into the brain by nasal insufflation.

公开(公告)号：US09695262B2

公开(公告)日：2017-07-04

申请号：US14000326

申请日：2012-02-24

Applicant: Subhra Mohapatra ,  Chunyan Wang

Inventor： Subhra Mohapatra ,  Chunyan Wang

IPC: C08F220/06 ,  C40B60/12 ,  C40B30/04 ,  G01N33/74 ,  B82Y5/00 ,  C07K14/58 ,  A61K38/00

CPC classification number: C08F220/06 ,  A61K38/00 ,  B82Y5/00 ,  C07K14/58 ,  G01N33/74 ,  G01N2333/58 ,  G01N2600/00 ,  Y10T428/24802

Abstract: The present invention concerns molecularly imprinted polymers (MIPs) having an affinity for natriuretic peptides, such as atrial natriuretic peptide (ANP). In some embodiments, the MIP is a nanoparticle (a molecularly imprinted polymeric nanoparticle (MIPNP)). Other aspects of the invention include methods of preparing an MIP having affinity for a natriuretic peptide, methods for binding a natriuretic peptide in vitro or in vivo using an MIP of the invention, methods for interfering with the binding of a natriuretic peptide with its receptor in vivo, methods for reducing inflammation, cell growth, cell differentiation, or a cell proliferation disorder, methods for detecting natriuretic peptides, and devices and kits for sequestering and/or detecting natriuretic peptides.

公开(公告)号：US09675714B1

公开(公告)日：2017-06-13

申请号：US14186845

申请日：2014-02-21

Applicant: Subhra Mohapatra ,  Chunyan Wang

Inventor： Subhra Mohapatra ,  Chunyan Wang

IPC: A61K51/00 ,  A61M36/14 ,  A61K49/18 ,  A61K31/704 ,  A61K48/00 ,  A61K49/00

CPC classification number: A61K49/1881 ,  A61K31/704 ,  A61K47/6923 ,  A61K48/0041 ,  B82Y5/00

Abstract: Disclosed herein are theranostic nanoparticles configured for simultaneous delivery of a diagnostic moiety, drug moiety, and a gene therapy moiety. In one embodiment, the theranostic nanoparticles contain a super paramagnetic iron oxide chemotherapeutic loaded on a chitosan functionalized 2D graphene sheet with a gene therapy moiety attached to the surface of the chitosan functionalized 2D graphene sheet. Also disclosed are methods for making and administering theranositic nanoparticles configured for simultaneous delivery of a diagnostic moiety, drug moiety, and a gene therapy moiety.

公开(公告)号：US09550992B2

公开(公告)日：2017-01-24

申请号：US14361537

申请日：2012-12-03

Applicant: UNIVERSITY OF SOUTH FLORIDA ,  Shyam S. Mohapatra ,  Srinivas Nagaraj Bharadwaj ,  Subhra Mohapatra

Inventor： Shyam S. Mohapatra ,  Srinivas Nagaraj Bharadwaj ,  Subhra Mohapatra

IPC: C12N15/11 ,  C12N15/113 ,  C12Q1/68 ,  C12N5/0789 ,  C12N5/0784 ,  C12N5/0786

CPC classification number: C12N15/113 ,  A61K47/6807 ,  A61K47/6849 ,  A61K47/6929 ,  C12N5/0639 ,  C12N5/0645 ,  C12N5/0647 ,  C12N15/111 ,  C12N2310/141 ,  C12N2310/17 ,  C12N2320/30 ,  C12N2501/65 ,  C12Q1/6883 ,  C12Q2600/158 ,  C12Q2600/178

Abstract: Provided are methods and compositions for modulating the differentiation of a myeloid derived suppressor cell (MDSC). In particular, described herein are miR-142 polynucleotides and miR-223 polynucleotides that can be used to modulate differentiation of MDSCs. Increased differentiation of a MDSC population, or cells within an MDSC population, can be achieved by increasing the miR-142 and/or miR-223 polynucleotides in a MDSC.

Abstract translation: 提供了用于调节骨髓来源的抑制细胞（MDSC）的分化的方法和组合物。 特别地，本文描述了可用于调节MDSC的分化的miR-142多核苷酸和miR-223多核苷酸。 可以通过增加MDSC中的miR-142和/或miR-223多核苷酸来实现MDSC群体或MDSC群体内的细胞的增加的分化。

公开(公告)号：US09433682B2

公开(公告)日：2016-09-06

申请号：US13775560

申请日：2013-02-25

Applicant: Subhra Mohapatra ,  Chunyan Wang

Inventor： Subhra Mohapatra ,  Chunyan Wang

IPC: A01N63/00 ,  A01N65/00 ,  A61K47/36 ,  A61K9/51 ,  A61L27/44 ,  A61L27/52 ,  A61L15/44 ,  A61L15/46 ,  A61L15/60 ,  C12N5/00 ,  C08B37/08 ,  C08L5/08 ,  C08J3/075 ,  C08F292/00 ,  C08F251/00 ,  C08F290/06 ,  C08F220/54 ,  C08F222/10 ,  C08G83/00

CPC classification number: A61K47/36 ,  A61K9/5161 ,  A61L15/44 ,  A61L15/46 ,  A61L15/60 ,  A61L27/443 ,  A61L27/52 ,  C08B37/003 ,  C08F220/54 ,  C08F222/1006 ,  C08F251/00 ,  C08F290/062 ,  C08F292/00 ,  C08G83/001 ,  C08J3/075 ,  C08J2387/00 ,  C08L5/08 ,  C12N5/0068 ,  C12N2533/20 ,  C12N2533/72 ,  C08L33/00 ,  C08L71/02 ,  C08F220/52 ,  C08F220/06

Abstract: Provided herein is a hydrogel composition comprising a graphene, a chitosan, and a polyethylene (glycol) diacrylate (PEGDA) (PCG hydrogel). In some embodiments, the hydrogel further comprises a N-isopropylacrylamide (NIPAM) (TPCG hydrogel). Also provided is a method for differentiating a mesenchymal stem cell comprising contacting the cell with the PCG hydrogel. Further provided herein is a method for delivering a pharmaceutical composition to a cell comprising administering to the cell a TPCG hydrogel and the pharmaceutical composition.

Abstract translation: 本文提供包含石墨烯，壳聚糖和聚乙二醇（二醇）二丙烯酸酯（PEGDA）（PCG水凝胶））的水凝胶组合物。 在一些实施方案中，水凝胶还包含N-异丙基丙烯酰胺（NIPAM）（TPCG水凝胶）。 还提供了用于分化间充质干细胞的方法，包括使细胞与PCG水凝胶接触。 本文还提供了将药物组合物递送至细胞的方法，包括向细胞施用TPCG水凝胶和药物组合物。

公开(公告)号：US09063142B1

公开(公告)日：2015-06-23

申请号：US14229221

申请日：2014-03-28

Applicant: Subhra Mohapatra ,  W. Jack Pledger

Inventor： Subhra Mohapatra ,  W. Jack Pledger

IPC: G01N33/574 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/366

CPC classification number: G01N33/57434 ,  A61K31/366 ,  A61K31/52 ,  A61K31/522 ,  A61K31/5377 ,  A61K38/1709 ,  A61K45/06 ,  A61K2300/00

Abstract: A treatment for prostate cancer using cyclin-dependent kinase inhibitors (CKIs) and a method of determining patient sensitivity to such CKIs is provided. The effects of cyclin-dependent kinase inhibitors on the survival of prostate cancer cells was examined. Roscovitine, R-roscovitine, and CGP74514A were shown to induce the apoptosis of LNCaP and LNCaP-Rf cells, both of which express wild-type p53. The cyclin-dependent kinase inhibitors of the present invention induce the mitochondria-mediated apoptosis of prostate cancer cells by a dual mechanism: p53 accumulation and XIAP depletion.

Abstract translation: 提供了使用细胞周期蛋白依赖性激酶抑制剂（CKI）的前列腺癌治疗方法和确定患者对这种CKI敏感性的方法。 检查细胞周期蛋白依赖性激酶抑制剂对前列腺癌细胞存活的影响。 显示Roscovitine，R-roscovitine和CGP74514A诱导LNCaP和LNCaP-Rf细胞的凋亡，两者都表达野生型p53。 本发明的细胞周期蛋白依赖性激酶抑制剂通过双重机制诱导线粒体介导的前列腺癌细胞凋亡：p53积累和XIAP消耗。

公开(公告)号：US20150064116A1

公开(公告)日：2015-03-05

申请号：US14346330

申请日：2012-09-28

Applicant: Subhra Mohapatra ,  Chunyan Wang

Inventor： Subhra Mohapatra ,  Chunyan Wang

IPC: A61K48/00 ,  A61K49/18 ,  A61K47/48 ,  C12N15/85

CPC classification number: A61K48/0041 ,  A61K47/48192 ,  A61K47/4823 ,  A61K47/48907 ,  A61K47/48923 ,  A61K47/59 ,  A61K47/61 ,  A61K47/6935 ,  A61K47/6939 ,  A61K48/0033 ,  A61K49/1809 ,  A61K49/1857 ,  A61K49/1863 ,  A61K49/1875 ,  C12N15/85 ,  C12N15/88 ,  C12N2800/107 ,  C12N2810/859

Abstract: Provided herein are compositions comprising a micelle having a hydrophobic superparmagnetic iron oxide nanoparticle (SPION) core, a first coating comprising a cationic polymer, and a second coating comprising a polynucleotide. Also provided are methods of using the compositions for transfection and/or transformation of a cell with the polynucleotide. Further provided are methods of detecting transfection of a cell with the polynucleotide.

Abstract translation: 本文提供了包含具有疏水超磁性氧化铁纳米颗粒（SPION）芯的胶束，包含阳离子聚合物的第一涂层和包含多核苷酸的第二涂层的组合物。 还提供了使用组合物用于与多核苷酸转染和/或转化细胞的方法。 还提供了用多核苷酸检测细胞转染的方法。